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Background: Exacerbations of COPD are a major burden to patients, and yet little is understood 
about heterogeneity. It contributes to the current persistent one-size-fits-all treatment. To replace 
this treatment by more personalized, precision medicine, new insights are required. We assessed 
the heterogeneity of exacerbations by functional respiratory imaging (FRI) in 3-dimensional 
models of airways and lungs. 
Methods: The trial was designed as a multicenter trial of patients with an acute exacerbation 
of COPD who were assessed by FRI, pulmonary function tests, and patient-reported outcomes, 
both in the acute stage and during resolution. 
Results: Forty seven patients were assessed. FRI analyses showed significant improvements 
in hyperinflation (a decrease in total volume at functional residual capacity of -0.25±0.61 L, 
p#0.01), airway volume at total lung capacity (+1.70±4.65 L, p=0.02), and airway resistance. 
As expected, these improvements correlated partially with changes in the quality of life and 
in conventional lung function test parameters. Patients with the same changes in pulmonary 
function differ in regional disease activity measured by FRI. 
Conclusion: FRI is a useful tool to get a better insight into exacerbations of COPD, and sig-
nificant improvements in its indices can be demonstrated from the acute phase to resolution 
even in relatively small groups. It clearly visualizes the marked variability within and between 
individuals in ventilation and resistance during exacerbations and is a tool for the assessment 
of the heterogeneity of COPD exacerbations.
Keywords: COPD exacerbations, FRI, hyperinflation, chronic obstructive pulmonary disease, 
symptoms, heterogeneity
Introduction
COPD is a disease with an enormous personal and societal burden. Considerable 
proportions of the morbidity, mortality, and costs of this disease are related to exac-
erbations of COPD.1 Relatively little is known about exacerbations, and the quest to 
effectively prevent and manage them continues. Medical treatment of acute exacerba-
tions routinely consists of steroids, bronchodilators, antibiotics, additional oxygen, 
and sometimes assisted ventilation. Currently, a one-size-fits-all treatment for acute 
exacerbations is provided in most clinics. We and many others believe that this should 
urgently be replaced by more personalized, precision medicine. 
Some tools have been developed to more adequately monitor the start and resolution 
of an exacerbation. Progress is definitely being made in the field of patient-reported 
outcome measurements (PROMs), such as the EXACT-PRO®, COPD Assessment 
Test (CAT), and Clinical COPD Questionnaire (CCQ).2,3 Traditionally, COPD patients 
are monitored by pulmonary function tests such as the forced expiratory volume in 
1 second (FEV
1
). However, especially during exacerbations, changes in FEV
1
 are small 
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and correlate poorly with patient-reported complaints such as 
dyspnea and with the response to medication.4–6 Both clini-
cians and researchers struggle with this issue on a daily basis. 
Therefore, new and more informative correlates of disease 
severity and response are eagerly awaited to allow individual-
ized therapy, especially during exacerbations. A model for a 
differential approach depending on the inflammatory status 
has been developed, where eosinophilic inflammation and 
bacterial infections help guide therapy. However, this does 
not address viral infections.7,8 Furthermore, we believe that 
hyperinflation, which has been shown to be important in 
guiding therapy in a stable state, should also be addressed 
during acute exacerbations.1,9–12
Hyperinflation is caused by trapping of air during expi-
ration, due to peripheral airway obstruction. It increases 
functional residual capacity (FRC) in such a way that 
inspiratory capacity (IC) decreases, resulting in increased 
dyspnea and limitation of exercise capacity.5,10,13–15 Some 
data about hyperinflation during exacerbations are avail-
able, showing that it increases.5,15 Whether the increase in 
hyperinflation during exacerbations is specifically caused 
by changes in the peripheral airways and decreased expi-
ratory time at times of greater demand remains unknown. 
Hyperinflation during exacerbations has been studied mostly 
by IC, yielding limited data, on aggregated level only. 
The result of this measurement is driven by several more 
regional factors, contributing differently between patients. 
Insightful knowledge of changes in hyperinflation during 
exacerbations is currently lacking, which is most mecha-
nistically unsatisfactory, and hampers the development of 
personalized treatment.
Next to hyperinflation, increased airway resistance has 
been observed in exacerbations.5,16,17 Airway resistance corre-
lates with dyspnea and recovery and stable state bronchodila-
tor response.5,16,17 Until this point, the heterogeneity of airway 
resistance has not been measured in exacerbations, although 
a technique to measure this value has been developed in the 
stable state of COPD.18 Clinical consequences of regional dif-
ferences in airway resistance thus far are not available, perhaps 
since this technique has been developed only recently. 
This promising new computational technique to better 
understand the mechanisms of acute exacerbations is 
called functional respiratory imaging (FRI).18 Based on 
high-resolution computed tomography (HRCT) scans, 
3-dimensional models of airways and lung are extracted and 
used for computational fluid dynamics (CFD) simulations. 
The technique has been extensively tested in stable COPD and 
other diseases and is clinically validated.18–21 One of the core 
features of FRI is that local measurements of lobar volumes, 
airway volumes, and airway resistance can be performed, 
while for instance the FEV
1
 incorporates the whole respira-
tory system into a single number. The usefulness of FRI has 
been proven in assessing hyperinflation, airway resistance, 
and airway diameter during stable state of COPD, but no data 
are available in the acute setting.20,22,23
This study was designed to test whether FRI has addi-
tional value on top of assessing conventional lung function 
tests and patient-reported outcomes (PROs) in the monitoring 
of patients with an exacerbation of COPD. We hypothesized 
that it is feasible to measure FRI also in the setting of acute 
exacerbations of COPD and that changes in FRI parameters 
correlate with changes in lung function parameters and PROs 
during resolution of COPD exacerbations, especially for 
FEV
1
 and hyperinflation. The inherent regional aspects of FRI 
should allow the detection of heterogeneity in exacerbating 
COPD patients.
Methods
The trial was designed as an international multicenter 
prospective cohort study. Patients were recruited from 
3 hospitals in Belgium, Italy, and the Netherlands. Protocols 
and patient information were all approved by the designated 
medical ethics committees (Comite voor medische Ethiek, 
Universiteit Ziekenhuis Antwerpen, Comitato Etico [per 
la sperimentazione clinica dei medicinali] dell’Azienda 
Ospedaliero Universitaria Careggi, and Medische Ethische 
Toetsingscommissie, Universitair Medisch Centrum Gron-
ingen). The trial was registered as NCT01684384 at www.
ClinicalTrials.gov.
Patients were recruited at the start of an exacerbation, 
when written informed consent was obtained. The treatment 
of the exacerbation was applied as usual care, according to 
the Global initiative for chronic Obstructive Lung Disease 
(GOLD) guidelines, and consisted at least of additional 
bronchodilation and systemic corticosteroids.24
A patient was eligible for inclusion only if all of the 
following criteria applied: aged $40 years; diagnosed with 
COPD with postbronchodilator FEV
1
/forced expiratory vital 
capacity (FVC) ,70% and postbronchodilator FEV
1
 ,80% 
predicted as documented in the last 5 years; and having a 
COPD exacerbation defined as an acute change in the patient’s 
baseline dyspnea, cough, and/or sputum that is beyond normal 
day-to-day variations and that necessitated the administra-
tion or doubling of systemic corticosteroid treatment. 
Patients were excluded from participation if any of the 
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heterogeneity of COPD exacerbations
patients diagnosed with asthma; and patients with pneumonia 
as defined radiologically at the start of the exacerbation, a 
history of or the presence of lung cancer, and an indication 
for noninvasive ventilation. Patients who were unlikely to 
comply with the protocol or unable to understand the nature, 
scope, and possible consequences of the study were also 
excluded, as were patients who had received any investiga-
tional new drug within the last 4 weeks prior to visit 1. Due to 
the recommendations of the medical ethics committee in the 
Netherlands, patients with a weight .110 kg were excluded, 
in the Netherlands only.
Measurements
PrOs
All measurements detailed below were obtained within 
5 days of the start of the exacerbation, and repeated at a 
stable state, ie, day 42, provided that the exacerbation had 
resolved as judged by their physician. Otherwise, the stable 
state measurements were postponed.
Health-related quality of life and dyspnea score were 
measured by validated PROMs: the Saint George’s Respi-
ratory Questionnaire (SGRQ), CCQ, CAT, and Modified 




, IC, FVC, residual volume, total lung capacity (TLC) 
by plethysmography, FRC, and airway resistance (by plethys-
mography [Raw]) were measured at both visits, according to 
the recommendations of the European Respiratory Society 
(ERS) guidelines with the accompanying reference values.26 
All lung function tests were repeated, until 3 technically 
acceptable measurements had been made, with a maximum of 
8 measurements. There was no withholding of bronchodilator 
treatment for the lung function measurements. 
CT
During the exacerbation, and in a clinically stable state, HRCT 
scans at FRC and TLC during breath-hold were performed. 
In order to ensure that the scans were taken at the correct lung 
function level, FRC and TLC were ensured by lung function 
technician coaching with the aid of a spirometer. Specific CT 
settings are reported in the Supplementary material. 
Postprocessing of the CT data included segmentation 
of the airway tree (Mimics; Materialise, Leuven, Belgium). 
Three-dimensional models of airways and lungs were 
extracted from scan and were used for CFD simulations. FRI, 
a clinically validated computational workflow, was used to 
perform measurements of lobar volumes (by FRI [iVlobe] “i” 
designates “imaging”), a parameter for lung hyperinflation. 
It was also used to assess airway volumes (by FRI [iVaw]) 
and airway resistances (by FRI [iRaw]; Figure 1). It has the 
potential to measure all these parameters at all lobes, at dif-
ferent airway generations and time points. We predefined the 
most important parameters: changes from exacerbation to 
stable state in the total score of both lungs for the parameters 

















Figure 1 Overview of the FRI concept. Patients are first scanned. Then, the CT images are segmented, and the rendering of the airways is calculated. Then, a 3-dimensional 
model of the lung is developed. Finally, flow is simulated in this model using CFD techniques.18
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The primary goal was to assess, during the resolution of an 
exacerbation, the strength of the association between change 
in lung function and change in parameters measured by FRI. 
The secondary goal was to assess the strength of the associa-
tion between the changes in the same FRI parameters and 
SGRQ, CAT, mMRC, and CCQ.
statistical analyses
A power calculation was based on an estimated correla-
tion coefficient of 0.7 for the primary objectives with 95% 
confidence interval of 0.52–0.80. The number of subjects 
needed to achieve 80% power with α of 0.05 was 50 (2-sided 
sample size calculation for a Pearson correlation analysis 
derived by Power and Precision™ 4.0 [Biostat, Englewood, 
NJ, USA]). 
The analyses were performed by using R Version 3.2.3 
(The R Foundation for Statistical Computing, Vienna, 
Austria). All continuous variables (imaging-based volumes 
and CFD-based resistances, lung function parameters, and 
PROMs) were tested for normality using Shapiro–Wilk 
W tests and transformed if necessary and successful.
Paired Student’s t-tests were used to evaluate the changes 
in these parameters from exacerbation to recovery. These 
tests were also used to check for the segmentation repro-
ducibility of the FRI measurements. Two-sided testing was 
performed.
Correlations between the continuous variables (the 
changes) were examined using multiple regression analy-
sis techniques. The analysis of variance was used to fit 
the model, and goodness-of-fit statics were performed. 
A p-value ,0.05 was defined as statistically significant. 
Parameters are reported as mean ± standard deviation for 
descriptive statistics and ±standard error of the mean for 
evaluative statistics.
Results
Between October 2012 and August 2014, a total of 54 patients 
were enrolled in this trial: 38 patients in Belgium, 6 patients in 
the Netherlands, and 10 patients in Italy. Table 1 presents 
the main characteristics of the recruited patients. Forty-seven 
patients were evaluable due to 7 dropouts (3 participants 
died, 3 withdrew consent, and 1 was lost to follow-up). All 
the participants were Caucasian.
Changes from exacerbation to stable state
Parameters of FRI improved from the acute phase to 
resolution of the exacerbation (Table 2; Figures 2 and 3). 
A significant improvement was found in hyperinflation, 
ie, a decrease in total volumes (iVlobe, total) at FRC 
of -0.25±0.61 L (p#0.01). Similarly, iVaw (total) at TLC 
increased, 1.70±4.65 L (p=0.02), though not at FRC. The 
iRaw at both FRC and TLC levels decreased significantly 
during recovery (Table 2).
Significant improvements were also found in FEV
1
, IC, 
and FRC (Table 2), as well as in airway resistance measured 
by plethysmography. Patients reported significant improve-
ments in health-related quality of life (SGRQ, CCQ, and 
CAT). All improvements were greater than the minimal 
clinical important difference and therefore also clinically 
significant.
Correlations of FrI parameters with 
lung function and PrOMs
The strength of the association between the changes from 
exacerbation to stable state in conventional lung function 
parameters (FEV
1
, IC, and Raw) and changes in parameters 
measured by FRI (iVaw, iVlobe, and iRaw) was assessed. 
Change in FEV
1
 was correlated with specific airway volumes 
(by FRI [siVaw], FRC; p=0.02, r=0.34). The change in airway 
resistance measured by plethysmography was correlated with 
change in airway resistance measured by FRI (iRaw, p=0.04). 
The changes in FEV
1
, specific airway resistance measured 
by pulmonary function test, and IC were not correlated with 
the changes in iVaw, specific airway resistance measured by 
FRI (siRaw), and iVlobe. Changes in CCQ and CAT were 
correlated with changes in FRI-based siRaw. Changes in 
mMRC were correlated with changes in siVaw. By contrast, 
the changes in PROs did not correlate significantly with 
changes in iVlobe or iVaw (Table 3).
Table 1 Patient characteristics (n=47)
Patient characteristics Value
sex (male/female) 27/20
age (years) 68.0±9.9 
gOlD stage 2/3/4 19/22/6
Current smokers/ex-smokers/never smokers 13/33/1
Pack-years 46.5±22.2
Treatment in outpatient setting/hospital setting 9/38
Days between exacerbation and stable state measurements 55.1±22.7
Notes: results are shown as mean ± standard deviation or n. Demographics 
presented were measured during screening, and the lung function data presented in 
this table were measured at stable state.
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heterogeneity of COPD exacerbations
FrI measures versus global patient changes
We have taken a deeper look at 2 patients from those within this 
trial. Both were female GOLD stage III COPD patients, aged 
57 and 62 years, with a smoking history of 35 and 20 pack-
years (hereafter they will be referred as patient 1 and patient 
2, respectively). Both patients present similar FEV
1
 values at 
baseline (39.0% predicted and 40.5% predicted) as well as a 
similar change in FEV
1
 after recovering from an exacerbation 
(3.0% predicted and 2.1% predicted). Even though the spirom-
etry measurements are same for both patients, FRI parameters 
show clear differences between them. Table 4 and Figures 4 
and 5 show the detailed overview of the FRI parameters.
At baseline, patient 1 is clearly hyperinflated, with a 
total lung volume of 140.6% predicted at TLC and 201.1% 
predicted at FRC in opposition to patient 2 (95.4% predicted 
at TLC and 118.5% predicted at FRC). When looking at 
changes in the FRI parameters, the increase in FEV
1
 is mainly 
associated with a decrease in iVlobe (6.1% at TLC and 28.3% 
at FRC) for patient 1 and only partially associated with 
change in resistance. On the other hand, patient 2 has a 
slight increase in iVlobe (1.4% at TLC and 4.9% at FRC), 
particularly in the upper lobes, but here the increase in FEV
1
 
can be linked to larger iVaw values at FRC (+95.72%) and a 
corresponding drop in resistance (-90.80%).
These results suggest that FRI is a technique that can 
differentiate between patients with comparable spirometry 
measurements. Therefore, FRI may result in more precise 
diagnosis and treatment, particularly in heterogeneous 
diseases such as COPD.
Discussion
We showed that FRI is feasible in the acute setting of COPD 
exacerbations. It can demonstrate significant differences 





















Figure 2 Variability in changes from exacerbation to stable state in iVlobe at TlC in individual patients (8 patients randomly selected). The scale represents the percent 
change in the volume of the different lung lobes at TlC; red represents an increase in volume, while blue represents a decrease.
Abbreviations: iVlobe, lobar volume measured by FrI; TlC, total lung capacity.
Table 2 Change from exacerbation to stable state in lung function and FrI parameters
Parameters At exacerbation At stable state Mean change Significance
FeV1 (l) 1.15±0.43 1.31±0.50 0.16±0.25 ,0.01*
FeV1 (% predicted) 45.92±15.05 51.89±16.83 5.97±9.15 ,0.01*
iVawFrC (ml) 34.78±14.20 36.28±12.87 1.50±7.65 0.19
iVawTlC (ml) 54.79±16.05 56.49±16.32 1.70±4.65 0.02*
FrC (l) 4.83±1.31 4.62±1.17 -0.22±0.58 0.01*
iVlobeFrC (l) 5.01±1.18 4.75±1.10 -0.25±0.61 ,0.01*
TlC (l) 6.72±1.42 6.74±1.30 0.02±0.60 0.81
iVlobeTlC (l) 6.47±1.18 6.49±1.14 0.02±0.41 0.76
raw (kPa⋅s/l) 0.71±0.24 0.63±0.34 -0.10±0.29 0.04*
irawFrC (kPa⋅s/l) 0.11±0.13 0.06±0.08 -0.04±0.12 0.03*
irawTlC (kPa⋅s/l) 0.04±0.03 0.04±0.02 -0.01±0.02 0.03*
IC (l) 1.96±0.59 2.20±0.73 0.14±0.27 ,0.01*
rV (l) 3.87±1.23 3.66±1.02 -0.21±0.76 0.07
TCO (mmol/min/kPa) 3.52±1.50 3.53±1.63 0.06±0.67 0.54
Patient-reported outcomes
sgrQ 62.18±15.31 48.60±20.51 -14.62±18.88 ,0.01*
CCQ 3.40±1.20 2.41±1.30 -1.00±1.45 ,0.01*
CaT 24.06±7.81 18.23±8.13 -5.83±11.28 ,0.01*
mMrC 3.11±1.15 2.43±1.17 -0.67±1.23 ,0.01*
Notes: Values are shown as mean ± sD. Correlations are reported as p-value and r. *p-value ,0.05. 
Abbreviations: CaT, COPD assessment Test; CCQ, Clinical COPD Questionnaire; FeV1, forced expiratory volume in 1 second; FrC, functional residual capacity; 
FrI, functional respiratory imaging; IC, inspiratory capacity; iraw, airway resistance measured by FrI; iVaw, airway volume measured by FrI; iVlobe, lobar volume measured 
by FRI; mMRC, modified Medical Research Council dyspnea scale; Raw, airway resistance measured by plethysmography; RV, residual volume; SD, standard deviation; SGRQ, 
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correlate partially with changes in conventional lung func-
tion parameters and the quality of life. It clearly visualizes 
regional heterogeneity within patients and large differences 
between them. 
FRI allows individualized measurements of patients with 
an acute exacerbation of COPD and among others visual-
izes the marked differences between patients. It does not 
measure a pulmonary function test with CT, but it measures 
different parameters. The parameters, hyperinflation, airway 
diameter, and air resistance, specifically of the lungs and seg-
ments within the lungs, are measured without bias from the 
oropharynx, eg, cough and oxygen masks. Importantly, the 
FRI parameters improve after the recovery of exacerbation. 
Since a CT scan can be performed during an acute event, even 
when conventional pulmonary function testing is not well 
possible, these findings might influence treatment decisions 
in the future, both for the group of acute exacerbations and 
for individuals. 
Next to the feasibility of FRI during exacerbations, this 
study also showed the ability to measure different regions of 
the lung during COPD exacerbations. One could have thought 
that volume and resistance changes during exacerbations 
were evenly distributed throughout the lung; however, our 
study showed in a small group marked changes between dif-
ferent regions. Next, changes in FEV
1
 after an exacerbation 
are not always determined by changes in the larger airways, 





















Figure 3 Variability in changes from exacerbation to stable state in siraw at TlC in individual patients (8 patients randomly selected). The scale represents the percent 
change in the resistance of the different airway branches at TlC; red represents an increase in resistance, while blue represents a decrease.
Abbreviations: siRaw, specific airway resistance measured by FRI; TLC, total lung capacity.
Table 3 Correlation between change in FrI parameters and 
changes in classical pulmonary function tests and in the quality of 
life, from exacerbation to stable state
Change in pulmonary 
function parameter or 
patient-reported outcome





FeV1 (l) iVlobe (FrC) 0.26 0.08
FeV1 (l) iVaw (TlC) 0.21 0.16
FeV1 (l) siVaw (FrC) 0.34 0.02*
IC (l) iVlobe (FrC) 0.35 0.06
IC (l) iVaw (TlC) 0.09 0.62
IC (l) siVaw (FrC) 0.05 0.78
raw iraw (FrC) 0.33 0.04*
sraw siraw (TlC) 0.13 0.42
secondary end points
sgrQ FeV1 (l) 0.24 0.11
sgrQ iVlobe (FrC) 0.14 0.38
sgrQ iVaw (TlC) 0.12 0.45
sgrQ siVaw (FrC) 0.17 0.26
sgrQ siraw (TlC) 0.28 0.07
CCQ FeV1 (l) 0.20 0.17
CCQ iVlobe (FrC) 0.24 0.11
CCQ iVaw (TlC) 0.12 0.41
CCQ siVaw (FrC) 0.14 0.34
CCQ siraw (TlC) 0.36 0.01*
CaT FeV1 (l) 0.38 0.01*
CaT iVlobe (FrC) 0.26 0.08
CaT iVaw (TlC) 0.26 0.08
CaT siVaw (FrC) 0.17 0.24
CaT siraw (TlC) 0.42 ,0.01*
mMrC FeV1 (l) 0.31 0.04*
mMrC iVlobe (FrC) 0.12 0.45
mMrC iVaw (TlC) 0.17 0.25
mMrC siVaw (FrC) 0.36 0.01*
mMrC siraw (TlC) 0.30 0.045*
Notes: Correlations are reported as p-value and r. *p-value ,0.05.
Abbreviations: CaT, COPD assessment Test; CCQ, Clinical COPD 
Questionnaire; FeV1, forced expiratory volume in 1 second; FrC, functional residual 
capacity; FrI, functional respiratory imaging; IC, inspiratory capacity; iraw, airway 
resistance measured by FrI; iVaw, airway volume measured by FrI; iVlobe, lobar 
volume measured by FRI; mMRC, modified Medical Research Council dyspnea scale; 
raw, airway resistance measured by plethysmography; rV, residual volume; sgrQ, 
the Saint George’s Respiratory Questionnaire; sRaw, specific airway resistance 
measured by pulmonary function test; siRaw, specific airway resistance measured 
by FRI; siVaw, specific airway volumes measured by FRI; TCO, transfer factor for 
carbon monoxide; TlC, total lung capacity.
Table 4 Changes in functional respiratory imaging parameters 
from exacerbation to stable state in 2 individual patients with 
similar changes in classical pulmonary function tests





FeV1 0.82 l +7.32 0.77 l +9.09
iVawFrC 32.41 ml -6.29 7.37 ml +95.72
iVawTlC 42.20 ml +14.79 29.13 ml +3.06
FrC 4.86 l -9.88 2.92 l +12.67
iVlobeFrC 201.13% predicted -28.33 118.52% predicted +4.87
TlC 6.22 l -0.96 4.59 l +3.92
iVlobeTlC 140.62% predicted -6.14 95.35% predicted +1.43
raw 0.441 kPa⋅s/l +20.18 1.060 kPa⋅s/l -18.96
irawFrC 0.05 kPa⋅s/l +5.51 0.17 kPa⋅s/l -89.90
irawTlC 0.09 kPa⋅s/l -51.35 0.05 kPa⋅s/l -0.82
Abbreviations: FeV1, forced expiratory volume in 1 second; FrC, functional 
residual capacity; iraw, airway resistance measured by FrI; iVaw, airway volume 
measured by FrI; iVlobe, lobar volume measured by FrI; raw, airway resistance 
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heterogeneity of COPD exacerbations
this influence is different in different subjects. To gain a more 
complete overview about this heterogeneity and its clinical 
implications, a study of larger sample size with a treatment 
algorithm is required. However, one could imagine that this 
new described intrapatient heterogeneity of the lung func-
tion can be of interest for future practitioners, since treating 
different lung regions might require different strategies.12 
Could regional guided treatment be of use during exacerba-
tions as well? Are those exacerbations with increased airway 
resistance the ones requiring a more frequent, higher dosed 
nebulizer treatment, such as asthma?
Thus far, no specific therapies for local differences in 
resistance have made it into daily clinical practice. During 
exacerbations, the presence and magnitude of effects of 
bronchodilators on resistance are not routinely assessed at all. 
FRI allows for measurement of airway resistance at several 
levels and has the potential to demonstrate and visualize dif-
ferences between severity and location of individual patients. 
It was not possible to detect whether changes are caused by 
mucus, airway wall thickening, muscle contraction, or other 
causes. Differences between the individuals can be expected 







Figure 4 FrI images of 2 patients displaying the changes in airway volume. The scale represents the percent change in the volume of the different airway branches at the 
different lung levels. green represents an improvement, while red represents a worsening. The airway volume is the volume of the lumen of the airways and does thus 
represent the volume of air inside the airways. The airways are measured starting from the trachea at the top of the sternum up to the point where no distinction can be 
made between the intraluminal and alveolar air. This is where the airway diameter is around 1–2 mm. One can infer that an increase in airway volume means bronchodilation 
has occurred.18
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van geffen et al
help to identify the best strategy based on airway resistance 
during exacerbations. 
This study shows the feasibility of measuring FRI param-
eters during exacerbations and compared the results with 
stable state. In clinical routine, the feasibility of lung function 
testing in patients admitted with an exacerbation of COPD 
is limited due to several reasons such as staff attendance, 
the absence of plethysmography, and the clinical condition 
of the patient. Since a CT scan can be performed during an 
acute event, even in patients in severe respiratory distress 
when conventional pulmonary function testing is not well 
possible, FRI might have a specific future role in the clini-
cal assessment of COPD exacerbation. Costs and radiation 
however need to be considered. 
FRI could be used to assess the parameters of increased 
hyperinflation during the exacerbation. Then, FRI could aid 
in individualizing treatment, above all of the bronchodilators. 
In patients who, after initial bronchodilation, show persistent 
hyperinflation, the effect of additional bronchodilation should 
be examined. Based on the distribution of the hyperinfla-
tion, bronchodilator device selection may be performed: for 
instance, regular nebulizers in case of central hyperinflation 
and pressurized metered-dose inhalers with spacer in more 
peripheral hyperinflation. Another potential strategy could be 
the selection of the type of bronchodilator. In stable COPD, 
long-acting bronchodilators have replaced short-acting bron-
chodilators in patients with a more severe hyperinflation. 







Figure 5 FrI images of 2 patients displaying the changes in lobar volume. The scale represents the percent change in the volume of the different airway branches at the 
different lung levels; green represents an improvement, while red represents a worsening.
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heterogeneity of COPD exacerbations
to treat patients with more hyperinflation with long-acting 
bronchodilators compared with the current standard treat-
ment of short-acting bronchodilators in less hyperinflated 
patients.6 In addition, different physiotherapeutic strategies, 
eg, to regulate breathing next to sputum evacuation, can be 
considered for this group, and in the long run perhaps non-
invasive lung volume reduction techniques, currently tested 
only in stable, though severely obstructed patients, could 
perhaps be attempted, as guided by FRI.27,28
It would be of great clinical importance if FRI measure-
ments can also aid in delineating the absence of hyperinflation 
and small airway dysfunction, a markedly different phenotype 
of exacerbation. Some of these patients suffer predominantly 
from fear and should be reassured and treated for their anxi-
ety, as opposed to more bronchodilators. The latter by induc-
ing tachycardia and giving false hopes might even augment 
fear. We speculate that FRI especially in combination with 
other biomarkers such as eosinophilia or viral and bacterial 
diagnosis will allow more precise assessments in acute exac-
erbations, potentially unlocking precision treatment. 
This study has several strengths and weaknesses that 
should be mentioned. It has been performed in different cen-
ters in different countries each with their own local radiologic 
and pulmonary function equipment making the applicability 
of its results broader: it is feasible in several different clinical 
settings. The correlations between the standard pulmonary 
function measurements and the FRI measurements were 
relatively low, which should not be a surprise given the 
difficulty of assessing them during exacerbations. During 
exacerbations, all measurements, including classical lung 
function, will be more variable than during stable state, low-
ering all correlations. At current, the variability in all these 
tests, including spirometry, during exacerbations is largely 
unknown and should be examined. The usefulness of all tests 
to adequately guide clinical decisions should be assessed, 
as much of the FRI measurements as of, for instance, FEV
1
, 
which is not routinely performed during acute exacerbations 
probably for good reason. Survival, hospital readmission, 
length of stay, and response to therapy should be considered 
as end points in future trials assessing treatment strategies. 
Conclusion
In summary, we have shown for the first time that FRI based 
on HRCT measurements is feasible also in patients with an 
acute exacerbation of COPD. During the resolution of the 
exacerbation, the parameters indeed improve considerably. 
The changes do correlate to some degree with changes in 
conventionally measured parameters such as change in FEV
1
, 
resistance, and hyperinflation, as well as with PROs, but also 
provide additional information. The technique clearly visual-
izes the marked variability within and between individuals 
in ventilation and resistance during exacerbations. Informa-
tion about regional differences in patients and heterogeneity 
between patients can now be obtained. 
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